Cytogen Corp. has won marketing approval in Denmark for itsmonoclonal antibody-based cancer imaging agent for colorectalcancer.
The Princeton, N.J., company previously had received approvalsin the United Kingdom, the Netherlands, Germany andLuxembourg. OncoScint CR103 will be sold in Europe throughEuroCetus, Cytogen's exclusive marketing partner.
Cytogen stock (NASDAQ:CYTO) closed down 13 cents at $15.63.
(c) 1997 American Health Consultants. All rights reserved.